Array Jumps as Colon Cancer Combo Helps Patients Live Longer

(Bloomberg) -- Shares of Array BioPharma Inc. climbed as much as 17%, the most since February, after results in colon cancer suggest the drug-maker may have the first chemotherapy-free regimen targ...

Bloomberg Quint

Add BloombergQuint App to Home screen.